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Abstract
Background: Dietary long-chain n-3 polyunsaturated fatty acid (PUFA) supplementation may be beneficial for chronic brain
illnesses, but the issue is not agreed on. We examined effects of dietary n-3 PUFA deprivation or supplementation,
compared with an n-3 PUFA adequate diet (containing alpha-linolenic acid [18:3 n-3] but not docosahexaenoic acid [DHA,
22:6n-3]), on brain markers of lipid metabolism and excitotoxicity, in rats treated chronically with NMDA or saline.
Methods: Male rats after weaning were maintained on one of three diets for 15 weeks. After 12 weeks, each diet group was
injected i.p. daily with saline (1 ml/kg) or a subconvulsive dose of NMDA (25 mg/kg) for 3 additional weeks. Then, brain fatty
acid concentrations and various markers of excitotoxicity and fatty acid metabolism were measured.
Results: Compared to the diet-adequate group, brain DHA concentration was reduced, while n-6 docosapentaenoic acid
(DPA, 22:5n-6) concentration was increased in the n-3 deficient group; arachidonic acid (AA, 20:4n-6) concentration was
unchanged. These concentrations were unaffected by fish oil supplementation. Chronic NMDA increased brain cPLA2
activity in each of the three groups, but n-3 PUFA deprivation or fish oil did not change cPLA2 activity or protein compared
with the adequate group. sPLA2 expression was unchanged in the three conditions, whereas iPLA2 expression was reduced
by deprivation but not changed by supplementation. BDNF protein was reduced by NMDA in N-3 PUFA deficient rats, but
protein levels of IL-1b, NGF, and GFAP did not differ between groups.
Conclusions: N-3 PUFA deprivation significantly worsened several pathological NMDA-induced changes produced in diet
adequate rats, whereas n-3 PUFA supplementation did not affect NMDA induced changes. Supplementation may not be
critical for this measured neuropathology once the diet has an adequate n-3 PUFA content.
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Introduction
The central nervous system is highly enriched in the polyun-
saturated fatty acids (PUFAs) arachidonic acid (AA, 20:4n-6) and
docosahexaenoic acid (DHA, 22:6n-3). AA and DHA cannot be
synthesized de novo by vertebrates, but must be obtained from the
diet or by hepatic elongation and desaturation of their dietary
essential precursors, linoleic acid (LA, 18:2n-6) and a-linolenic
acid (a-LNA, 18:3n-3), respectively [1,2]. The balance between
AA and DHA is crucial for normal brain function [3,4]. AA is a
precursor of prostaglandins, thromboxanes, leukotrienes, and
related compounds that have important roles in inflammation
and in the regulation of brain immunity. DHA and its metabolites
are thought to be neuroprotective and to have anti-inflammatory
effects [5]. AA signaling in brain is mediated by Ca2+-dependent
cytosolic phospholipase A2 (cPLA2), while DHA signaling is
mediated by Ca2+-independent phospholipase A2 (iPLA2) [6].
North American diets tend to contain low levels of DHA and
high levels of n-6 PUFAs derived primarily from LA [7–9]. Some
epidemiological studies suggest that reduced dietary n-3 PUFA
content is associated with an increased risk of neuropsychiatric and
neurodegenerative disorders [10], in which excitotoxicity is
present [11,12].
Animal studies have been performed to understand how diet-
derived n-3 PUFAs influence body integrity and metabolism. In
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rats, a DHA-free diet containing a-LNA at 4.6% of total fatty acid
is sufficient to maintain normal growth and organ function, so this
diet is considered n-3 PUFA ‘‘adequate’’ [1,13]. In contrast, in rats
fed a DHA-free diet containing low amounts of a-LNA (0.2% of
dietary fatty acids), brain DHA concentration is reduced, behavior
is disturbed and brain derived neurotrophic factor (BDNF) is
reduced compared with the adequate 4.6% a-LNA diet, so this
diet is considered n-3 PUFA ‘‘inadequate’’ or ‘‘deficient’’ [13–15].
Brain changes in rats fed the n-3 PUFA deficient diet include a
prolonged DHA half-life, an increased concentration of docosa-
pentaenoic acid (DPAn-6, 22:5n-6) derived from liver elongation
of AA, and reduced expression of DHA-metabolizing iPLA2
[16,17] and cyclooxygenase (COX)-1 enzymes [17]. Additionally,
n-3 PUFA deprivation increases brain expression of enzymes that
regulate AA metabolism, including cPLA2 Type IVA, sPLA2 Type
II and COX-2 [17].
Effects of n-3 PUFA deprivation and supplementation on brain
markers during physiological or pharmacological insults are
uncertain. Several studies reported that dietary n-3 PUFA
deficiency affected brain glutamatergic, dopaminergic and seroto-
nergic systems [16–18]. Hyperglutamatergic activity is reported in
neurodegenerative and neuropsychiatric illnesses such as Alzhei-
mer disease (AD) [11], Parkinson disease [19] and bipolar disorder
[20,21]. Glutamate is the main excitatory neurotransmitter in
brain and is involved in learning and memory, brain development
and aging, and excitotoxicity [21–23]. Glutamate exerts some of
its effects via ionotropic N-methyl-D-aspartate [NMDA], alpha-
amino-3-hydroxy-5-methyl-4-isoxazolepropionate [AMPA] and
kainate receptors, and via G-protein coupled metabotropic
glutamate receptors [24]. We reported that a chronic daily
subconvulsive dose of NMDA (25 mg/kg i.p.) in adult rats
decreased brain NMDA receptor subunit levels [21], and
upregulated mRNA and protein levels of interleukin-1 beta (IL-
1b), tumor necrosis factor alpha (TNF-a), glial fibrillary acidic
protein (GFAP) and inducible nitric oxide synthase (iNOS) in the
frontal cortex [25]. Furthermore, chronic NMDA increased AA
turnover in rat brain phospholipids, and upregulated cPLA2 IVA
mRNA, protein and activity, and the cPLA2 transcription factor
activation protein AP-2 [21].
The extent of dietary n-3 PUFA protection against excitotox-
icity is not agreed on. We designed this study to understand
whether dietary n-3 PUFA deficiency or supplementation could
modify chronic NMDA-induced changes in rat brain AA
signaling, neuroinflammatory markers and trophic factors. To
do this, we maintained rats on an n-3 PUFA deprived, adequate or
supplemented (by fish oil) diet for 15 weeks after weaning. After
the initial 12 weeks, each of the three groups of animals was
administered saline or a subconvulsive dose of NMDA (25 mg/kg,
i.p.) daily for 3 weeks. The rats were sacrificed at 15 weeks and
their brains were used to measure lipid concentrations, and
molecular markers of lipid metabolism, neuroinflammation,
BDNF and nerve growth factor (NGF).
Table 1. Dietary compositions of n-3 PUFA adequate, n-3 PUFA deficient and NIH-31 diets.
n-3 PUFA adequate diet1 n-3 PUFA deficient diet1 NIH -312
g/100 g diet g/100 g diet g/100 g diet
Protein 20 20 18
Carbohydrate 60 60 65
Fat 10 10 4.7
Ash 1 1 8
Fatty acids % of total fatty acids % of total fatty acids % of total fatty acids
14:0 12.5 14.60 1.4
14:1 n-5 0.04 0.05 N/A
16.0 9.5 9.9 15.7
16:1n-7 0.04 0.13 1.5
18:0 8.0 8.0 3.2
18:1 n-9 8.4 5.9 20.60
18:2 n-6 27.9 27.20 47.5
18:3 n-3 4.6 0.20 5.1
20:5n-3 (EPA) None None 1.9
22:6-n-3 (DHA) None None 2.4
Total Saturated 58.8 66.50 0.90
Total monosaturated 8.5 6.1 1.20
Total n-6 PUFA 27.9 27.20 18.8
Total n-3 PUFA 4.6 0.2 9.4
n-6/n-3 6.1 136 2
Fatty acid content mmol/g diet
18:2 n-6 40.5 35.8 59.0
18:3 n-3 6.7 0.21 5.9
1Adapted from reference [27].
2Composition of the NIH-31 diet was determined by gas-chromatography.
doi:10.1371/journal.pone.0095318.t001
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Methods
Ethics Statement
This protocol was approved by the Animal Care and Use
Committee of the Eunice Kennedy Shriver National Institute of Child
Health and Human Development, and followed the National
Institutes of Health Guide for the Care and Use of Laboratory
Animals (NIH Publication 86–23).
Animals
Eighteen to 20 day-old male CDF rat pups weighing 30–40 g,
and their nursing surrogate mothers, were purchased from Charles
River Laboratories (Portage, MI, USA). The pups were not
littermates. The animals were housed in a facility with regulated
temperature (24uC) and humidity (40–70%), under a 12 h light/
dark cycle. They were allowed to nurse until 21 days old, then
removed from their mothers, mixed without identification, and
assigned randomly to one of three dietary groups: an n-3 PUFA
adequate diet (4.6% a-LNA of total fatty acids, no DHA), fish oil
supplemented diet (5.1% a-LNA of total fatty acids, 1.9% EPA
and 2.4% DHA) (Zeigler Bros, Gardners, PA, USA) and an n-3
PUFA deficient diet (a-LNA is 0.2% of total fatty acids, no DHA)
(Dyets, Inc. Bethlehem, PA, USA). The specific diet compositions
are reported elsewhere [26,27].
The n-3 PUFA and deficient diets were based on the AIN-93
diet and differed with regard to fat composition. The n-3 PUFA
adequate diet contained 6.0, 3.2 and 0.8 (g/100 g diet) hydroge-
nated coconut oil, safflower oil and flaxseed oil, respectively, while
the n-3 PUFA deficient diet contained 6.6, 3.4 and 0 (g/100 g diet)
hydrogenated coconut oil, safflower oil and flaxseed oil, respec-
tively. The fish oil supplemented diet was based on the NIH-31
diet which contains EPA and DHA. The composition of the diets
is provided in Table 1. We used these three diets in particular
because we previously reported their effects on PUFA metabolism
in the brain and liver of rats. There is no difference in brain DHA
quantity, DHA turnover, and brain DHA incorporation between
rats fed the NIH 31 fish oil diet and the n-3 PUFA adequate DHA-
free diet even when dietary composition is not matched [28,29].
After 12 weeks on a dietary regimen, rats in each group (n= 16
per group) received vehicle (0.9% saline, n = 8) or NMDA (25 mg/
kg body weight, n = 8) (Sigma Aldrich, St. Louis, MO, USA) by
intraperitoneal injection once daily for 21 days. The rats were
maintained on their respective diets for three more weeks. Three
hours after the last saline or NMDA injection, a rat was
anesthetized with an overdose of CO2 and decapitated. The brain
was rapidly excised and cut sagittally into four sections, which
were used for lipid analysis, Western blotting, mRNA analysis and
enzyme activity assays. Brain sections were frozen in 2-
methylbutane, and stored at 280uC until further use.
During the course of NMDA treatment, one rat from each of
the n-3 deficient and n-3 adequate groups treated with NMDA
was euthanized because they exhibited a spontaneous tonic-clonic
seizure. The lipid and molecular biology analyses were done on 6
out of the remaining 7 or 8 animals per group.
Brain lipid composition analysis
Brain total lipids were extracted with chloroform/methanol (2:1
v/v) from one quarter of brain, derivitized in 1% methanolic
H2SO4 and analyzed by gas chromatography as previously
described [30].
Preparation of cytosolic fractions for Western blot
analysis
Cytosolic brain fractions were prepared as reported [31].
Briefly, one quarter section of the left hemisphere was homoge-
nized in a buffer containing 20 mM Tris-HCl (pH 7.4), 2 mM
EGTA, 5 mM EDTA, 1.5 mM pepstatin, 2 mM leupeptin,
0.5 mM phenylmethyl sulfonylfluoride, 0.2 U/ml aprotinin, and
2 mM dithiothreitol, using a Polytron homogenizer. The homog-
enate was centrifuged at 100,000 g for 60 min at 4uC, and the
resulting supernatant (cytosolic fraction) was collected. Protein
concentration of the cytosolic fraction was determined using Bio-
Rad Protein Reagent (Bio-Rad, Hercules, CA, USA).
PLA2 enzyme activities
Activities of individual PLA2 enzymes were measured in the
cytosolic fraction as described in detail elsewhere [11,32], with
slight modifications to the extraction. For cPLA2 activity, a portion
of the cytosolic fraction was incubated in 100 mol/L 1-palmitoyl-
2-arachidonoyl-sn-glycerol-3-phosphorylcholine (Avanti, Alabas-
ter, AL, USA) and phosphatidylinositol 4,5-bisphosphate (97:3)
containing approximately 100.000 cpm of 1-palmitoyl-2-[1-14C]
arachidonoyl-sn-glycerol-3-phosphorylcholine (Perkin-Elmer, Bos-
ton, MA, USA) and 4,5 biphosphatidylinositol (Avanti) in
400 mol/L triton X-100 mixed micelles containing 100 mmol/L
Hepes, pH 7.5, 80 mol/L calcium, 2 mmol/L DTT, and 0.1 mg/
mL fatty acid free bovine serum albumin. For iPLA2 activity, a
portion of the cytosolic fraction was incubated in 100 mmol/L 1-
palmitoyl-2-palmitoyl-sn-glycerol-3-phosphorylcholine (Avanti)
containing approximately 100,000 cpm of 1-palmitoyl-2-[1-14C]
palmitoyl-sn-glycerol-3-phosphorylcholine (Amersham, Buckin-
ghamshire, UK) in 400 mmol/L Triton X-mixed micelles in
100 mmol/L HEPES, pH 7.5, 5 mmol/L EDTA, 2 mmol/L
DTT, and 1 mmol/L ATP.
Assays were started by adding reagent to cytoplasmic extracts
(0.3 mg in one assay) for 30 min at 40uC in a shaking bath.
Reactions were terminated by adding Dole’s reagent (2-propanol:
heptane: 0.5 mol/L sulfuric acid, 400: 100: 20, by volume)
followed by vortexing. Released [1-14C] fatty acids were extracted
with the addition of heptane and water. One milliliter of the
heptane was loaded on a bond elute reservoir with a frit pre-
loaded with silicic acid. The unesterified [1-14C] fatty acids were
eluted from the silicic acid by adding diethyl ether with the help of
a vacuum. Radioactivity of the eluant was determined by liquid
scintillation counting and activity was calculated after correcting
for the background of blank samples. All samples were run in
triplicate and values are expressed in pmol/min/mg of protein.
sPLA2 activity. sPLA2 activity was measured using an
appropriate assay kit (Cayman Chemical, Ann Arbor, MI),
according to the manufacturer’s instructions.
Western blot analysis of protein levels
Proteins from the cytosolic fraction (65 mg) were separated on
4–20% SDS-polyacrylamide gels (PAGE) (Bio-Rad), and electro-
phoretically transferred to a nitrocellulose membrane (Bio-Rad).
Cytosolic protein blots were incubated overnight in Tris-buffered-
saline containing 5% nonfat dried milk and 0.1% Tween-20, with
specific primary antibodies for proinflammatory cytokines: IL-1b
(1:500), GFAP (1:1000), cPLA2-IVA, sPLA2-IIA, iPLA2-VIA,
COX-1 (1:500) and COX-2 (1:200) (Santa Cruz Biotechnology,
Santa Cruz, CA, USA); and b-actin (1:10,000) as a housekeeping
protein (Sigma Aldrich). The cytosolic blots were incubated with
appropriate horseradish peroxidase (HRP)-conjugated secondary
antibodies (Bio-Rad), and were visualized using a chemilumines-
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Figure 1. Brain lipid composition and activity of AA cascade enzymes. Brain lipid composition in nmol/g brain of A) Body weights B) AA C)
DHA D) n-6 DPA. Data are expressed as mean 6 SEM (n = 6 per group). Statistical significance is denoted by * p#0.05, ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0095318.g001
Figure 2. cPLA2 activity and protein expression. Measured activity of A) cPLA2 enzymes and B) cPLA2 protein levels. Data are expressed as
mean 6 SEM (n= 6 per group for activity, or n = 5-6 per group for protein, due to unquantifiable bands). Statistical significance is denoted by * p#
0.05, ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0095318.g002
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cence reaction (Amersham, Piscataway, NJ, USA). Optical
densities of immunoblot bands were measured using Alpha
Innotech Software (Alpha Innotech, San Leandro, CA, USA)
and were normalized to b-actin. All experiments were conducted
on six independent samples. Mean values are expressed as percent
of control.
BDNF and NGF protein determination
BDNF and NGF protein levels were determined with respective
ELISA kits (Sigma Aldrich) following the manufacturer’s recom-
mendations. Values are expressed as percent of control.
Statistics
A two-way ANOVA was used to determine main effects of diet
and NMDA on brain fatty acid concentrations and activity,
Figure 3. sPLA2 activity and protein expression.Measured activity of A) sPLA2 enzymes and B) sPLA2 protein levels. Data are expressed as mean
6 SEM (n= 5–6 per group for activity due to a negative activity value of 22.37 in the fish oil-NMDA group that was removed, and 5 per group for
protein due to unquantifiable bands). Statistical significance is denoted by * p#0.05, ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0095318.g003
Figure 4 iPLA2 activity and protein expression. Measured activity of A) iPLA2 enzymes and B) iPLA2 protein levels. Data are expressed as mean
6 SEM (n= 6 per group for activity, and 5 per group for protein due to one unquantifiable band per group). Statistical significance is denoted by * p#
0.05, ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0095318.g004
n-3 PUFA Modification of NMDA-Induced Neuropathology
PLOS ONE | www.plosone.org 5 May 2014 | Volume 9 | Issue 5 | e95318
mRNA and protein levels. A one-way ANOVA followed by
Newman-Keuls Multiple Comparison post-hoc test was used to
compare the differences between the adequate-saline vs. n-3
PUFA deprived saline or fish oil-saline groups. Statistical
significance also was calculated among the three groups (n-3
PUFA adequate saline vs. n-3 PUFA adequate –NMDA, n-3
PUFA deprived vs. n—3 PUFA –NMDA group and Fish oil-
Saline vs. Fish oil-NMDA group). Data are expressed as mean 6
SEM. Statistical significance is denoted by * p#0.05, ** p#0.01,
*** p#0.001.
Results
There was a significant main NMDA and diet effect, and
NMDA and diet interaction on body weight (p,0.05 by two-way
ANOVA). At 15 weeks, mean body weight of fish oil-saline
administered rats was significantly less compared to weight of the
adequate group-saline administered rats (Fig. 1A). However, body
weight was significantly increased in diet-adequate rats given
chronic NMDA compared with saline (Fig. 1A).
Brain lipid composition
A two-way ANOVA showed no significant main effect of
NMDA or interaction of diet x NMDA on brain AA, DPA n-6 and
DHA concentrations with all the three n-3 PUFA diets. There was
a significant diet effect on PUFA concentrations with each of the
three diets (Fig. 1). The brain AA, DPA n-6 and DHA
concentrations did not differ significantly between NMDA and
saline administered rats in each diet group (Fig. 1B). DPAn-6
concentration was significantly higher, and DHA concentration
was significantly lower, in saline treated rats from the n-3 PUFA
deprived compared to adequate group (Figs. 1C and 1D). Fish oil
supplementation did not alter brain AA, DHA or n-6 DPA
concentration compared to respective concentrations with the
adequate diet (Figs. 1B, C, and D).
Effect of diet and NMDA on arachidonic acid cascade
markers
A two-way ANOVA showed a significant diet and NMDA main
effect on brain cPLA2 activity. Chronic NMDA compared with
saline significantly increased cPLA2 activity in each of the three
dietary groups (Fig. 2A). cPLA2 activity with chronic saline was
significantly increased in n-3 PUFA deprived compared with the
adequate group (3.4 fold: p,0.0001), but unchanged by fish oil
supplementation (Fig. 2A). The same two-way ANOVA analysis
showed a significant NMDA effect but no significant interaction of
diet x NMDA on brain cPLA2 protein with the three diets.
Whereas diet had no effect on cPLA2 protein in saline treated rats,
chronic NMDA compared with saline significantly elevated cPLA2
IVA protein in rats fed the n-3 adequate or supplemented diet but
not the deprived diet (Fig. 2B).
Mean sPLA2 activity and protein levels were not significantly
changed (Figs. 3A and 3B), and a two-way ANOVA showed no
significant diet x NMDA interaction, or main effects on sPLA2 IIA
protein.
A two-way ANOVA showed a significant diet (P = 0.0013) and
NMDA (p=0.0043) effect on iPLA2 activity. Mean iPLA2 activity
was decreased significantly in the n-3 PUFA deprived compared to
adequate rats given chronic saline (Fig. 4A), but iPLA2 activity was
not increased by supplementation. A two-way ANOVA showed a
significant diet x NMDA interaction (p= 0.0376) on iPLA2 VIA
protein (Fig. 4B). Post-hoc analysis with one-way ANOVA showed
no statistically significant differences between the groups
(p = 0.054).
There was a main effect of diet (p = 0.0016) and NMDA
(p= 0.039) on COX-2 and COX-1 protein. However, post-hoc
Figure 5. COX protein level. Measured protein levels of A) COX-1 and B) COX-2. Data are expressed as mean 6 SEM (n = 5 per group for protein
due to one unquantifiable band per group). Statistical significance is denoted by * p#0.05, ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0095318.g005
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analysis by one-way ANOVA showed that chronic NMDA
compared with chronic saline did not significantly alter the
COX-1 or COX-2 protein level in the deficient or supplemented
compared with adequate diet group (Figs. 5A and B), and in each
of the three groups NMDA did not have a significant effect on
protein levels.
Effects of diet on neuroinflammatory markers and
neurotrophic factors
Protein levels of the astrocytic marker GFAP and of inflamma-
tory cytokine IL-1b were not significantly changed by diet in the
saline treated rats (Figs. 6A and B). There was a significant main
effect of diet (p = 0.0033) and NMDA (0.0032) on BDNF protein,
although post-hoc analysis by one-way ANOVA did not show
significant differences in the deficient or fish oil groups compared
to the adequate group, or between saline and NMDA treatment
within each diet (Fig. 4C). NGF protein was not significantly
altered by diet or NMDA in all the dietary groups (Fig. 4D).
Discussion
This study confirms that chronic NMDA administration
compared with saline control produces a number of changes in
brain lipid metabolism, markers of neuroinflammation and growth
factors in n-3 PUFA diet adequate rats. Dietary n-3 PUFA
deprivation below the adequate level exacerbated these changes,
whereas supplementation did not dampen them. In n-3 PUFA
adequate rats fed 4.6% a-LNA but no DHA, NMDA compared
with saline increased body weight, cPLA2 activity and cPLA2 IVA
protein, but decreased iPLA2 protein and BDNF. Deprivation to
an a-LNA content of 0.2% of total fatty acid, significantly changed
NMDA responses compared with saline treated group and
increase cPLA2 activity and protein was observed. In rats
supplemented with n-3 PUFA via fish oil, NMDA compared with
saline also increased cPLA2 activity and cPLA2 IVA protein.
Significant diet effects as noted by ANOVAs and post-hoc
comparisons with the adequate group occurred in DHA and
DPAn-6 concentrations (DHA decreased and DPAn-6 increased
with n-3 PUFA deprivation), body weight (decreased by supple-
mentation), cPLA2 activity (increased by deprivation) and iPLA2
activity (decreased by deprivation). Thus, deprivation worsened or
did not change pathological markers induced by chronic NMDA
in rats fed the adequate diet, whereas supplementation did not
affect these markers significantly but did reduce body weight. In
agreement with our findings, dietary n-3 PUFA supplementation
reduced weight gain and improved postprandial lipidemia and the
Figure 6. Neuroinflammatory cytokine and neurotrophin gene expression. Mean protein levels of A) IL-1b, B) GFAP C)BDNF D) NGF. Data
are expressed as mean 6 SEM (n= 4–5 per group for IL-1b, 4–6 per group for GFAP, 5–6 per group for BDNF, and 6 per group for NGF. Some groups
had less than n= 6 due to unquantifiable bands). Statistical significance is denoted by * p#0.05, ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0095318.g006
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associated inflammatory response in the obese JCR:LA-cp rat
[33], whereas dietary n-3 PUFA deprivation did not change body
weight [34].
Clinical reports indicate that dietary supplementation of long-
chain n-3 PUFAs can correct some behavioral or neurocognitive
symptoms in bipolar disorder and Alzheimer disease patients, and
that low n-3 PUFA intake may exacerbate these symptoms [35–
38]. Rodent studies suggest that reduced dietary n-3 PUFA
increases brain pro-inflammatory markers such as AA cascade
enzymes and reduces the neurotrophic factor BDNF [21,39]. In
the present study, we found that 15 weeks of n-3 PUFA
deprivation increased NMDA-induced brain cPLA2 activity and
protein levels. Deprivation also reduced iPLA2 activity and protein
as well as BDNF protein. Deprivation increased the brain
concentration of n-6 DPA while reducing DHA concentration,
whereas supplementation had no significant effect on any of the
three concentrations. Although, supplementation may not provide
significant protection against NMDA excitotoxicity if the adequate
dietary requirement of n-3 PUFA is satisfied, supplementation
might be helpful where liver damage or genetic alterations in n-3
PUFA metabolic enzymes exist.
The dietary ratio of AA to DHA affects various brain signaling
pathways including protein kinases A and C and MAPK p38 [21].
Changes in these protein kinases were reported to affect BDNF in
rat brain [40]. The current study supports previous findings
showing decline in BDNF with deprivation. BDNF knockdown/
knockout mice have increased depressive behavioral scores [40].
Increased AA metabolism has been linked to apoptosis with loss of
BDNF [41]. These findings suggest that an increase in AA
metabolism due to increased cPLA2 activity after n-3 PUFA
deprivation and/or an NMDA insult can affect neuronal integrity,
plasticity and behavior.
Chronic NMDA independently promotes neuronal death and
pro- and anti-apoptotic factors in rat brain [42]. An association
between increased expression of AA cascade enzymes and
neurocognitive impairments/neurodegeneration has been suggest-
ed for Alzheimer disease and vascular dementia [43,45]. The
present study suggests that n-3 PUFA deprivation upregulates AA
metabolism and amplifies the NMDA insult. These changes could
contribute to cognitive impairment, while attenuation of AA
release by inhibiting cPLA2 may be beneficial. Future studies
might examine effects of dietary supplementation in the presence
and absence of an NMDA antagonist on chronic NMDA induced
changes in rat brain.
Our findings may clarify whether dietary n-3 PUFA supple-
mentation is necessary in human subjects [45]. The brain DHA
concentration did not significantly differ between adequate vs. fish
oil supplemented diets and it seems that slight reductions in
circulating DHA in humans would not necessarily have patho-
physiological consequences. Supporting this suggestion, a 33%
lesser blood DHA concentration in vegetarians than in omnivores
[46] was not associated with a significant difference in mood, or in
general mortality or mortality from any cause [47,48]. Moreover,
4-month dietary DHA supplementation in preschool children,
which increased blood DHA from 1.0% to 3.2% of total fatty
acids, did not enhance scores on any of four cognitive tests [49].
There are two limitations with this study. First, the fat
composition of the n-3 PUFA supplemented (fish oil) diet was
50% lower than that of the n-3 adequate and deficient diets
(Table 1). This may explain the lower body weights of the
supplemented group compared to the adequate and deficient
groups. Second, the LA composition of the fish oil diet was 1.75
times higher than that of the adequate and deficient groups. This
may explain why the fish oil supplemented diet did not prevent
NMDA-induced changes in AA cascade and neuroinflammatory
markers. In agreement with this suggestion, one study reported a
reduction in headache frequency in chronic migraine patients, in
which peripheral AA metabolism is upregulated, when fish oil
supplementation was combined with a low LA diet [50]. Fish oil
supplementation may be clinically beneficial when LA is
substantially reduced. The possible benefits of combining fish oil
with a low LA diet should be explored in future studies.
In conclusion, dietary deprivation of DHA precursor b-LNA in
the absence of dietary DHA reduced brain DHA and exacerbated
NMDA induced AA and inflammatory markers in rat brain.
Supplementation did not suppress upregulated NMDA induced
markers in rat brain.
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